Investment area
Seed Investments
Region
Europe
Date of investment
October 2023
LimmaTech Biologics AG is applying its deep expertise in engineering complex carbohydrate molecules to develop next-generation vaccines to prevent life-threatening diseases. Spun out from GlycoVaxyn after that company was acquired by GSK, LimmaTech Bio is advancing its own proprietary clinical pipeline to halt the increasing threat of global infections due to emerging antimicrobial resistance and sexually transmitted infections such as gonorrhoea, alongside partnered programmes with GSK. LimmaTech is committed to translating novel scientific concepts into highly effective vaccines that benefit humanity.
Contact
Camilla Petrycer Hansen
Partner
Department: Seed Investments
Camilla Hansen joined Seed Investments in June of 2018.
Camilla brings 10 years of business development experience from early academic start-up to industry. Most recently, Camilla was responsible for scouting and building new growth platforms for Novozymes A/S. Prior to that, Camilla held a business development position at Statens Serum Institute (SSI) where she was commercializing preclinical and clinical life science products and projects, in addition to being instrumental in divesting the Vaccine Production business from SSI.
From 2009 to 2012 she worked in technology transfer at Wake Forest University Health Sciences in the US where she was involved in out licensing and commercializing early and mid-stage assets, including company creation.
Camilla has a PhD in Medicinal Chemistry and a Master of Pharmacy degree from Copenhagen University.
